In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Obinutuzumab in Lupus Nephritis
Community PollStarted
Do you utilize B cell depleting agents as induction therapy in patients with lupus nephritis?
77 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Rheumatology · Hackensack University Medical Center
Answered on
I agree with @Dr. @Dr. First Last's previous answer (posted July 2020). In addition, the 2024 ACR Lupus Nephritis guidelines (discussed at the 2024 ACR meeting) still recommend mycophenolate (MMF) or cyclophosphamide as first-line induction therapies for lupus nephritis (LN), rather than B-cell depl...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Rheumatology · Beth Israel Deaconess Medical Center
Answered on
B-cell directed therapies with or without a standard of care (SoC) are not regarded as first-line therapies for lupus nephritis. Following the case series of successful treatments of lupus nephritis with rituximab, the LUNAR study showed that rituximab+SoC improved immunologic parameters but not cli...
Join for free or sign in to see the full answer